Your employer is about to spend more money keeping you alive than a lot of Americans make in a year. Benefits consultant Aon is projecting that employer health care costs will hit $19,000 per employee in 2027, a 9.5% increase that marks yet another year in what is quietly becoming one of the worst sustained stretches of health care inflation in modern American history. The bill keeps growing. Somehow, so does yours.
The Number That Should Make You Sit Down
Let's put $19,000 in context for a second. The federal poverty line for a single adult in 2026 sits around $15,000. So your employer is, on paper, spending more to insure you than millions of Americans have to live on entirely. And according to Axios, which reported on the Aon projections, this is the third consecutive year of near double-digit cost increases. This isn't a spike. This is a pattern.
Aon, one of the largest benefits consulting firms in the country, attributes the surge to a familiar trio of culprits: rising demand for health services broadly, more Americans living with chronic illness, and the absolutely explosive uptake of GLP-1 drugs like Ozempic and Wegovy. Those weight loss and diabetes medications are miraculous, expensive, and increasingly everywhere. They are doing real work on the cost side of the ledger.
What 'Employer Costs Rising' Actually Means for You
Here's the part that tends to get buried when outlets cover these projections. When employer health costs go up, employers have options. They can absorb it, which squeezed-margin companies rarely do enthusiastically. They can cut other compensation. Or they can shift costs to employees through higher premiums, bigger deductibles, narrower networks, and more aggressive prior authorization requirements.
Guess which option has historically been most popular? Every year for roughly the last two decades, the trend has been consistent: the sticker price goes up, the employer grabs a slightly larger share of the premium, and the employee gets handed a plan that covers a little less and costs a little more out of pocket. The $19,000 figure sounds generous until you realize that number is split between what the employer pays and what gets docked from your paycheck, and the employee's share keeps creeping up.
There's no Aon forecast for what workers will actually pay, because that depends on what thousands of individual companies decide to do. But the incentives are not pointing in your favor.
Why This Won't Stop on Its Own
The drivers Aon identified are not going away. Chronic disease in America is not getting better at a policy level. The number of Americans with diabetes, heart disease, obesity-related conditions, and mental health diagnoses has been climbing for years, and the health system's ability to prevent those conditions rather than just treat them remains, generously speaking, underfunded and underperforming.
GLP-1 drugs are a genuinely complicated piece of this story. On one hand, they work. Patients on semaglutide drugs show real reductions in heart attack and stroke risk, real weight loss, real improvement in metabolic conditions. On the other hand, a monthly supply can run $1,000 or more before insurance, and uptake is accelerating fast. Employers and insurers are covering more of these prescriptions than ever, which is good for patients and brutal for actuaries.
Rising demand for health services more broadly is the third leg of the stool. Axios notes that this is part of what's driving the Aon forecast, though the specific breakdown of which service categories are surging fastest wasn't detailed in the projection. Post-pandemic utilization has rebounded sharply across most specialties, and the system is still working through years of deferred care.
Three Years In, and Nobody's Solved This
What makes this particular stretch of health inflation politically interesting is how thoroughly it defies easy partisan framing. Republicans spent years arguing that the Affordable Care Act was making everything worse. Democrats spent years arguing the ACA was holding costs down. Neither talking point really captures a situation where employer-sponsored insurance, the dominant way working Americans get coverage, is in the middle of a three-year affordability crisis during a period of otherwise cooling general inflation.
The Biden years saw some meaningful drug pricing reforms through the Inflation Reduction Act, including the first-ever authority for Medicare to negotiate drug prices. The Trump administration, back in office since January 2025, has not exactly made health care affordability a signature domestic priority. Meanwhile, the people stuck in the middle of all this are HR departments trying to design benefits packages and workers trying to figure out whether they can afford to actually use the insurance they have.
Nine-point-five percent, on top of the three years before it, is not a blip. It is a structural crisis being treated like an annual inconvenience.
The Dingo Take
You are supposed to believe that a $19,000-per-employee price tag represents the market working. That competition among insurers, the invisible hand of consumer choice, and the bracing efficiency of American capitalism are churning toward some equilibrium that will eventually make this all make sense. Three consecutive years of near double-digit increases suggest otherwise.
The Aon projection is a business story about employer budgets and benefits consultants and actuarial spreadsheets. It's also a story about a country that has decided, through decades of policy choices and political cowardice, that health care should be a for-profit industry optimized for revenue rather than a public good optimized for outcomes. The $19,000 number is what you get when chronic disease goes unaddressed at the population level, when drug pricing is set by what the market will bear rather than what the medicine costs to make, and when the dominant response to a crisis is to keep hoping it works itself out.
It is not working itself out. Your deductible next year will be happy to confirm that.
Comments